Brian Druker
Director/Board Member presso AMGEN INC.
Patrimonio netto: 2 M $ in data 31/03/2024
Profilo
Brian J.
Druker is the founder of MolecularMD Corp.
(founded in 2005) and Blueprint Medicines Corp.
(founded in 2008).
He currently holds multiple positions, including Independent Director at Amgen, Inc. since 2018, Director & Associate Dean at Oregon Health & Science University since 2010, Director at The Burroughs Wellcome Fund, Independent Director at Vincerx Pharma, Inc. since 2020, and Director at OHSU Knight Cancer Institute since 2007.
Dr. Druker's education includes undergraduate and doctorate degrees from the University of California San Diego.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
AMGEN INC.
0.00% | 19/05/2023 | 5 688 ( 0.00% ) | 2 M $ | 31/03/2024 |
VINCERX PHARMA INC
0.26% | 25/05/2023 | 54 806 ( 0.26% ) | 277 318 $ | 31/03/2024 |
Posizioni attive di Brian Druker
| Società | Posizione | Inizio |
|---|---|---|
| AMGEN INC. | Director/Board Member | 23/05/2018 |
| VINCERX PHARMA, INC. | Director/Board Member | 23/12/2020 |
| Oregon Health & Science University | Director/Board Member | 01/07/2007 |
The Burroughs Wellcome Fund
 The Burroughs Wellcome Fund Investment Trusts/Mutual FundsMiscellaneous The Burroughs Wellcome Fund is a private foundation located in Research Triangle Park, NC. The private company's mission is to serve and strengthen society by nurturing a diverse group of leaders in biomedical sciences to improve human health through education and powering discovery in frontiers of greatest need. The CEO of the company is Louis J. Muglia. | Director/Board Member | - |
| OHSU Knight Cancer Institute | Director/Board Member | 01/07/2007 |
Precedenti posizioni note di Brian Druker
| Società | Posizione | Fine |
|---|---|---|
MolecularMD Corp.
 MolecularMD Corp. Medical/Nursing ServicesHealth Services MolecularMD Corp. develops and commercializes molecular diagnostics for oncology applications. Its tests are designed to assist pharmaceutical companies with selection, monitoring and management of patients treated with molecularly-targeted cancer therapies. The firm integrates gold-standard and innovative platform technologies with custom clinical assay design and validation to accelerate all phases of clinical development, including FDA approval and commercialization of in vitro companion diagnostic tests for novel anticancer agents. The company was founded by Brian Druker, Sheridan G. Snyder, and Chad D. Galderisi in 2005 and is headquartered in Portland, OR. | Founder | - |
| BLUEPRINT MEDICINES CORPORATION | Founder | - |
Formazione di Brian Druker
| University of California San Diego | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| AMGEN INC. | Health Technology |
| BLUEPRINT MEDICINES CORPORATION | Health Technology |
| VINCERX PHARMA, INC. | Health Technology |
| Aziende private | 3 |
|---|---|
The Burroughs Wellcome Fund
The Burroughs Wellcome Fund Investment Trusts/Mutual FundsMiscellaneous The Burroughs Wellcome Fund is a private foundation located in Research Triangle Park, NC. The private company's mission is to serve and strengthen society by nurturing a diverse group of leaders in biomedical sciences to improve human health through education and powering discovery in frontiers of greatest need. The CEO of the company is Louis J. Muglia. | Miscellaneous |
MolecularMD Corp.
MolecularMD Corp. Medical/Nursing ServicesHealth Services MolecularMD Corp. develops and commercializes molecular diagnostics for oncology applications. Its tests are designed to assist pharmaceutical companies with selection, monitoring and management of patients treated with molecularly-targeted cancer therapies. The firm integrates gold-standard and innovative platform technologies with custom clinical assay design and validation to accelerate all phases of clinical development, including FDA approval and commercialization of in vitro companion diagnostic tests for novel anticancer agents. The company was founded by Brian Druker, Sheridan G. Snyder, and Chad D. Galderisi in 2005 and is headquartered in Portland, OR. | Health Services |
| OHSU Knight Cancer Institute |
- Borsa valori
- Insiders
- Brian Druker
